Specific Binding of the Chemokine Platelet Factor 4 to Heparan Sulfate*

(Received for publication, December 17, 1996, and in revised form, March 25, 1997)

Sally E. Stringer Dagger § and John T. Gallagher

From the Cancer Research Campaign Dagger  Drug Development Department, Paterson Institute of Cancer Research and the  Medical Oncology Department (University of Manchester), Christie Hospital, Wilmslow Road, Manchester, M20 9BX, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Platelet factor 4 is a tetrameric heparin binding chemokine released from the alpha -granules of activated platelets. In this study we show that platelet factor 4 binds with high affinity and specificity to an approximately 9-kDa sequence in heparan sulfate, which it protects from degradation by heparinase enzymes. This protected fragment is enriched in N-sulfated disaccharides and iduronate 2-O-sulfate residues, the latter being important for binding to platelet factor 4. The major structural motif of the fragment appears to consist of a pair of sulfated domains positioned at both ends separated by a central mainly N-acetylated region. On the basis of these findings, we propose a model in which the heparan sulfate fragment wraps around the ring of positive charges on platelet factor 4 with the iduronate 2-O-sulfates within the sulfated domains binding strongly to lysine clusters on opposite faces of the tetramer.


INTRODUCTION

Platelet factor 4 (PF4)1 is a platelet-released cytokine, with a number of properties associated with inflammation and wound healing (for review see Ref. 1), some of which are thought to be due to its ability to neutralize the activities of heparin and heparan sulfate proteoglycans. PF4 has been proposed to exert procoagulant activity by preventing the formation of the stable heparin-antithrombin III-thrombin ternary complex (2). It also inhibits binding of heparin-binding growth factors such as basic fibroblast growth factor, vascular endothelial growth factor (splice variant 165), and transforming growth factor beta 1 to their receptors (3-5) and is antiangiogenic, having been shown to inhibit proliferation and migration of endothelial cells in vitro (6). Subsequent studies demonstrated the ability of PF4 in vivo to specifically bind to areas of active angiogenesis (7) and to inhibit the growth of murine melanoma and colon carcinoma, probably as a result of suppressing tumor-induced neovascularization (8, 9).

Carboxyl-terminal fragments of PF4 have been shown to retain some of the activities of whole PF4, such as blocking the interaction of bFGF with its receptor (10) and inhibiting angiogenesis (6). Two pairs of C-terminal lysines (residues 61 and 62 and residues 65 and 66) on an amphipathic alpha -helix in each PF4 monomer are thought to be important in binding heparin, since guanidation of these (11) or digestion with carboxypeptidase (12) decreases binding. However, NMR studies of PF4 suggested that arginines (residues 20, 22, and 49) in other regions of the protein are also critical to the interaction with heparin, and site-directed mutation of these arginines reduced heparin binding 7-fold (13). PF4 exists mainly as a tetramer at physiological ionic strength and pH (14), and its high affinity for heparin (11) appears to depend on a 1:1 ratio of tetramers to polysaccharide (15, 16). Models proposed from x-ray crystallographic and NMR studies (13, 17) support the hypothesis that heparin may wrap around the tetramer binding to a ring of positive charges running perpendicular to the lysine containing alpha -helices.

Heparin expression is restricted primarily to degranulating tissue-type mast cells (18), while heparan sulfates (HS) are a common pericellular constituent of mammalian cells (19, 20). The interaction of PF4 with HS proteoglycans may be physiologically relevant, since, following release from platelets, PF4 is thought to bind to HS proteoglycans on endothelial cells (21). In the present study we have examined the binding of PF4 to HS. The results indicate that the pattern of sulfation and spacing of the sulfated (S) domains are important for this interaction. On the basis of our findings we have proposed a model of PF4 binding to HS that may be relevant to other chemokines.


EXPERIMENTAL PROCEDURES

Materials

Platelet factor 4 was purified from human platelet concentrates (22). D-[6-3H]Glucosamine hydrochloride (20-45 Ci/mol) was obtained from NEN Life Science Products (Stevenage, UK). Heparinase I (Flavobacterium heparinum; EC 4.2.2.7), chondroitinase ABC (Proteus vulgaris; EC 4.2.2.4), N/O-desulfated N-resulfated heparin, and N/O-desulfated N-reacetylated heparin were from Seikagaku Kogyo Co. (Tokyo, Japan). Heparinase II (F. heparinum; no EC number assigned) and heparinase III (F. heparinum; EC 4.2.2.8) were obtained from Grampian Enzymes (Aberdeen, UK). Bovine lung heparin, selectively 6-O-desulfated heparin (approximately 66% of the 6-O-SO4 removed with most of the 2-O-SO4 present) and N-desulfated, N-reacetylated heparin were kindly provided by Dr B. Mulloy (National Institute for Biological Standards and Control, Hertfordshire, UK); 2-O- and 6-O-desulfated heparin were provided by Professor H. Baumann (Makromolekulare Chemie und Textilchemie, Aachen, Germany); and heparin desulfated at C-2 only was provided by Dr. B. Casu (Instituto Chemica e Biochemica, Milan, Italy). Carboxyl-reduced heparin was prepared by G. Rushton (Paterson Institute of Cancer Research, Christie Hospital, Manchester, UK) according to Taylor et al. (23). Biogel P10 and Affi-Gel 10 were purchased from Bio-Rad Laboratories (Hemel Hempstead, UK), Sepharose CL6B and DEAE Sephacel were purchased from Pharmacia Biotech Inc., and Heparin-agarose was purchased from Sigma (Poole, UK).

Radiolabeling and Preparation of Intact HS Chains

HS chains biosynthetically labeled with [3H]glucosamine were prepared from nearly confluent cultures of mouse 3T3 fibroblasts, as described by Lyon et al. (24) for fetal skin fibroblast HS. To remove any remaining amino acids from the core protein, the HS chains were incubated in 50 mM NaOH, 1 M NaBH4 overnight at room temperature, and the reaction was neutralized with acetic acid. The molecular size distribution of the material was then analyzed by gel filtration chromatography on a Sepharose CL6B column (1 × 100 cm) eluted with 0.25 M NH4HCO3 at a flow rate of 5 ml/h.

Filter Binding Assay

A modified version of the filter binding assay of Maccarana et al. (25) was used. Briefly, 3H-radiolabeled HS was incubated with 1 µg of PF4 plus any nonradioactive glycosaminoglycan inhibitors for 10 min at 37 °C in 10 µl of Tris buffer (130 mM NaCl, 50 mM Tris-HCl, pH 7.3). The volume was then made up to 300 µl by the addition of Tris buffer, and the samples were drawn through buffer-equilibrated cellulose nitrate filters on a vacuum manifold. The filters were washed with 2 × 5 ml of 130 mM NaCl, 50 mM Tris-HCl, and bound material eluted with 2 × 5 ml of 2 M NaCl, 50 mM Tris-HCl or the appropriate NaCl concentration in affinity experiments. On average greater than 99% of the radiolabeled material was removed from the filters with 2 M NaCl, 50 mM Tris-HCl.

To assess PF4 binding affinity for HS, Scatchard analysis of the data collected by the filter binding assay was used. The lines of best fit and graphical equations for the data were determined by Cricket Graph III Apple Macintosh computer software. The gradients of these lines are equivalent to -1/Kd(1) and -1/Kd(2), the x intercept for the first line represents the number of binding sites on the protein (n1), and the x intercept for the second represents n1 + n2, where n2 is the number of binding sites with Kd(2).

Specific Degradation of HS

Nitrous acid degradation was performed by the low pH method of Shively and Conrad (26). Degraded samples were neutralized by the careful addition of 1 M Na2CO3. Heparinase I and heparinase III (also known as heparitinase I) enzyme digestions were both performed with additions of 20 mIU/ml enzyme in 0.1 mM calcium acetate, 1 mg/ml bovine serum albumin, pH 7.0, at 30 °C for heparinase I or room temperature for heparinase III. To ensure maximum breakdown of HS, at least two additions of the enzymes were made over an 18-h period, with the final addition of heparinase III carried out at 37 °C for at least 1 h. The extent of breakdown was followed spectrophotometrically at 232 nm, or an aliquot of 3H-radiolabeled digest was checked on a Biogel P10 column (1 × 100 cm) eluted with 0.25 M NH4HCO3.

Preparation of the PF4-protected Domain (PPD) of HS

Approximately equimolar quantities of 3H-radiolabeled HS and PF4 (6 µM each) were preincubated for 10 min at room temperature before digestion by heparinase III, used at a final concentration of 70 mIU/ml enzyme in 0.5 mM calcium acetate, 50 mM NaAc, and 0.1 mg/ml bovine serum albumin, pH 7.0, in 140 µl for about 14 h at room temperature. A further addition of 10 mIU of heparinase III (in 50 µl of 0.5 mM CaAc, 50 mM NaAc, 0.1 mg/ml bovine serum albumin, pH 7.0) was made after 8 h, and finally an additional 10 mIU of enzyme were added for 2 h at 37 °C. The digest was then heated at 95 °C for 30 min to denature the enzyme and PF4. The resultant fragments were separated on a Biogel P10 column (1 × 100 cm) eluted with 0.25 M NH4HCO3, the void volume peak pooled and freeze-dried for 48 h to remove the NH4HCO3 and redissolved in distilled water. The molecular size of an aliquot was then checked on Sepharose CL6B. The sample was denatured for a further hour at 95 °C. The large molecular weight saccharide fragments were precipitated by the addition of 0.3 M sodium acetate and 3 volumes of 95% (v/v) ethanol for 2 h at -70 °C and pelleted by 15-min microcentrifugation at 13,000 rpm. The pellet was rinsed in 75% ethanol, air-dried, and redissolved in distilled water. For preparation of nonradiolabeled PF4-protected HS species, fractions from the P10 and CL6B gel columns were analyzed spectroscopically at 232 nm.

Affinity Chromatography

To prepare a PF4 affinity gel column, 500 µg of human PF4 was mixed with 500 µg of heparin in 100 µl of coupling buffer (0.1 M HEPES, 80 mM NaCl, pH 7.0) and incubated for 20 min at room temperature. The PF4 was then bound to Affi-Gel 10, and the column was prepared as described for an hepatocyte growth factor affinity column by Lyon et al. (24) alongside a control column where the PF4 was omitted.

Affinity experiments were performed by application of radiolabeled HS samples in a 20 mM sodium phosphate buffer of physiological ionic strength and pH, i.e. 0.15 M NaCl and pH 7.3. The sample of HS was recirculated through the column at least five times at room temperature to maximize its opportunity to bind to PF4. The column was then washed with 2.5 ml of 0.15 M NaCl, 20 mM sodium phosphate, pH 7.3, followed by 2.5 ml of each of NaCl concentrations from 0.2 to 1.5 M in 0.05 M increments. 0.5-ml fractions were collected and monitored for radioactivity.

To determine PF4 binding affinity for heparin, 5 µg of PF4 was loaded onto a column containing 500 µl of heparin-agarose gel slurry that had been equilibrated in 50 mM Tris, 0.13 M NaCl buffer. The PF4 was eluted with 4-ml steps of 50 mM Tris buffers containing NaCl concentrations ranging from 0.1 to 1.8 M in 0.1 M increments. 1-ml fractions were collected and monitored by spectroscopy at 260-nm absorbance.


RESULTS

Interaction of PF4 with HS

To examine the affinity of PF4 for HS, a filter binding assay was used (25). 1 µg of human PF4 was incubated with various quantities of 3H-labeled murine 3T3 fibroblast HS; the solution was passed through a cellulose nitrate filter, which adsorbs PF4 or the PF4-HS complex but not HS itself; and the proportion of bound HS was determined. The data were assessed by Scatchard analysis (Fig. 1A). PF4 binding approaches saturation at about 1000 nM HS, and a clear point of inflection is visible on the semilog plot (Fig. 1, inset), a requirement for Scatchard analysis (27). The curved shape of the Scatchard plot indicates that there must be more than one possible HS binding site on PF4. To enable calculation of approximate Kd values, two lines were fitted to the plot that intersected the x axis at 1.2 and 7.0 with gradients of -0.063 and -0.005, respectively (Fig. 1A, main plot). Therefore, at low ratios of HS to PF4, approximately 1 molecule of HS bound per PF4 tetramer with a Kd of 15.9 nM, whereas at higher HS concentrations the Kd of 200 nM indicated that six molecules bound with much lower affinity. The plot could be interpreted as a negative cooperativity curve, where increases in the number of molecules of HS binding in a range from one to six, due to increased HS:PF4 ratios, correlates with a decrease in the binding affinity.


Fig. 1. Filter binding assay of the interaction of PF4 with HS and other glycosaminoglycans. A, Scatchard analysis of HS binding to PF4. A range of concentrations of 3H-labeled HS chains were incubated with PF4, and the proportion of bound material was determined by filter binding as described under "Experimental Procedures." Two lines (solid lines) have been fitted to the curve using the software package Cricket Graph III, where Lb, Lf, and M represent the concentrations (in nM) of bound HS, free HS, and PF4 tetramers, respectively. The dashed lines indicate the intersects of the curves with the x and y axes, which are equivalent to the number of binding sites (n) for HS on the PF4 tetramer and n/Kd. The inset shows a semilog plot of the saturation curve of the same data. B, competitive inhibition of 3H-labeled HS chains binding to PF4 by unlabeled glycosaminoglycans. The inhibition curves are given for bovine lung heparin (open circle ····open circle ), porcine intestinal mucosal HS (bullet ------bullet ), and dermatan sulfate (× - - -×). Error bars (S.E. = S.D./radical number of samples) are visible where they exceed the symbol size. Each experiment was repeated at least three times.
[View Larger Version of this Image (22K GIF file)]

PF4 elution from a heparin affinity column was also determined to allow comparison with published studies of PF4 and other heparin-binding proteins. As expected from previous reports (11), PF4 applied at physiological ionic strength bound strongly to heparin and eluted between 1.1 and 1.6 M, with a median of 1.35 M, in a stepwise NaCl concentration gradient (data not shown).

Glycosaminoglycan Specificity of PF4 Binding

A range of glycosaminoglycans were examined for their ability to competitively inhibit binding of 1 µg (99 nM) of 3H-radiolabeled murine 3T3 fibroblast HS to 1 µg (107 nM) of PF4 tetramers, by the filter binding assay to give an insight into binding requirements (Fig. 1B). Although the heavily sulfated heparins were found to be the strongest inhibitors of binding, HS was a significantly more efficient inhibitor than the other glycosaminoglycans tested. Bovine lung heparin and porcine intestinal mucosal heparan sulfate inhibited binding at lower concentrations than the structurally distinct dermatan sulfate, with IC50 values of 0.03, 0.2, and 2 µg, respectively (Fig. 1B). Similarly, porcine intestinal mucosal heparin had an IC50 of 0.04 compared with 1.2 µg for chondroitin sulfate (data not shown). Binding of an equivalent amount of bFGF to HS, which is known to be a strong interaction (28), was inhibited by 0.2 µg of bovine lung heparin in the same assay.

Requirement of Particular Chemical Groups

Competition studies using a range of specifically modified heparins were carried out to determine which groups were important in the interaction with PF4. Replacement of the N-sulfates on the glucosamines with N-acetyl groups had no effect on the inhibitory activity of heparin, the IC50 remained at 0.04 ± 0.01 µg (mean ± S.E. to 2 decimal places). Partial 6-O-desulfation of heparin (66% depletion of 6-sulfate groups) only slightly increased the IC50 to 0.06 ± 0.01 µg, whereas removal of the 2-O-sulfates from the IdoAs increased the IC50 3-fold to 0.12 ± 0.00 µg, suggesting that the latter groups may be of particular importance in the interaction with PF4. The carboxyl groups also seem to be involved in the interaction as carboxyl reduction of the uronic acids increased the IC50 2-fold to 0.08 ± 0.00 µg. The IC50 for 2- and 6-O-desulfated heparin was particularly high at 5 µg, 125-fold higher than the intact polysaccharide, whereas the IC50 of totally desulfated heparin was so high it was not obtainable, being above 140 µg.

Effects of Specific Enzyme Scission

To identify domains important for PF4 binding, competition studies were carried out with porcine mucosal HS digested by the enzymes heparinase I and/or heparinase III that cleave the polysaccharide in different structural regions. Heparinase I acts in the N-sulfated regions and specifically cleaves disaccharides that contain 2-O-sulfated iduronate i.e. GlcNSO3(±6-OSO3)alpha 1,4IdoA(2-OSO3) (29). By contrast, heparinase III cleaves GlcA-containing disaccharides (29), principally GlcNAc/GlcNSO3alpha 1,4GlcA, that are present in regions of low sulfation and does not attack contiguous N-sulfated sequences that are enriched in IdoA. The binding to PF4 of HS fragments produced by heparinase I or heparinase III was significantly decreased by comparison with native HS. The IC50 values increased by approximately 3-fold in each case, to 0.52 ± 0.10 µg for heparinase I-digested HS and to 0.62 ± 0.06 µg for heparinase III-digested HS compared with 0.22 ± 0.00 µg for the intact HS. This indicates that both N-sulfated (S-domains) and N-acetylated regions of the HS chain are important for binding. Digestion of HS with both heparinase I and heparinase III together had a significant additive effect, further increasing the IC50 to 1.30 ± 0.05 µg.

Isolation of the PF4 Binding Site on HS (Protection Assay)

Since the PF4 binding site appeared to overlap both N-acetylated and N-sulfated regions of HS, the binding domain could not be isolated from fragments produced by scission with either heparinase I or heparinase III. Therefore, a protection assay was used in which PF4 was included in a heparinase digest to prevent cleavage of the binding site. Initial results (data not shown) demonstrated that the sizes of HS binding fragments protected by PF4 during digestion with either combined heparinases I and III or heparinase III alone were not significantly different, so most experiments were carried out with heparinase III. Native polyacrylamide gel electrophoresis of porcine HS/PF4 mixtures confirmed that no aggregates containing more than 1 PF4 tetramer were formed at the 1:1 ratios used (results not shown). A prolonged digest was carried out to ensure that all the heparan sulfate was digested apart from fragments with strong binding affinity for PF4. When the fragments (i.e. S-domains) from heparinase III breakdown of HS in the absence of PF4 were compared by gel filtration on a high resolution Biogel P10 column with profiles for PF4-protected HS (Fig. 2, A and B) the most striking difference was the presence of an obvious peak in the void volume of the PF4-protected digest (Fig. 2B). This was surmised to be the PPD. Gel filtration chromatography of PPD on Sepharose CL-6B revealed a radioactive fraction, the peak maximum of which eluted with a mean Kav (from several experiments) of 0.65 (Fig. 2C), equivalent to a mass of 9.3 ± 1.2 kDa by reference to the published calibration of Wasteson (30). This is equivalent to about 21 disaccharides, assuming an average of 450 Da/disaccharide. By comparison, the intact fibroblast HS had a Kav of 0.35, equivalent to approximately 40 kDa (Fig. 2C). A similar size fragment (10.7 kDa) was isolated from porcine intestinal mucosal HS protected by PF4.


Fig. 2. Heparinase III digestion of HS in the presence or absence of PF4: isolation of the PPD. 3H-Labeled HS chains were treated with heparinase III in the absence (A) or the presence (B) of an equimolar amount of PF4 as described under "Experimental Procedures." The digests were analyzed by chromatography on a Biogel P10 column. The void volume (Vo) in panel B (fractions 26-32) represents the PPD. In panel C, the molecular size of native HS chains (open circle ····open circle ), PPD (bullet ------bullet ), and PPD treated with heparinase I (square - - -square ) were compared by gel filtration on Sepharose CL6B. Vt, total volume.
[View Larger Version of this Image (19K GIF file)]

It was important to establish that PPD was indeed a PF4 binding fragment. Elution of intact HS and PPD from PF4 by a range of NaCl concentrations was examined by the filter binding assay, and the profiles were found to be similar, with both binding at up to 0.6 M NaCl (Fig. 3A). For comparison to PPD, fragments of decasaccharide size and above from a heparinase III digest of HS in the absence of PF4 were isolated, and the salt concentration at which they eluted from PF4 was tested in the filter binding assay. Half the amount of these single S-domains bound to PF4 compared with PPD, and they were completely eluted by 0.3 M NaCl (not shown), suggesting that they have significantly less affinity for PF4 than PPD.


Fig. 3. Comparison of the relative affinity of PPD and HS for PF4 by filter binding (A) and affi-gel chromatography (B and C). A, intact 3H-labeled HS (solid bars) or PPD (open bars) were incubated with 1 µg of PF4, and the PF4-bound [3H]HS were determined by filter binding assay. The columns show the effect of a range of salt concentrations on the interaction. Error bars of percentage of bound [3H]HS are depicted. 3H-Labeled HS chains (B) and PPD (C) were applied to a PF4 Affi-Gel column in 0.15 M NaCl. Bound material was eluted stepwise with a gradient of NaCl, increasing by 0.05 M at each step. The actual NaCl concentrations at which radiolabeled material was eluted are shown. The dotted line in panel B shows HS eluted from a control column under identical conditions.
[View Larger Version of this Image (19K GIF file)]

For further comparison between PPD and intact fibroblast HS, their relative affinities for a PF4 Affi-Gel column were compared. The majority of the bound intact HS and PPD eluted between 0.2 M and 0.4 M NaCl, again with similar elution profiles (Fig. 3, B and C). No further elution was seen from the remainder of the 0.05 M stepwise gradient taken up to 1.5 M NaCl. The apparent affinity of polysaccharide for the PF4 Affi-Gel may be less than with the filter binding due to the physical restrictions of PF4 being bound to the gel. Metabolically labeled HS prepared from bovine aortic endothelial cells exhibited slightly lower affinity for PF4 eluting mainly between 0.2 and 0.3 M NaCl (data not shown). A control column did not exhibit any binding of HS (Fig. 3B, dotted line) or PPD above 0.2 M NaCl.

Analysis of PPD Compared with Native HS

PPD was depolymerized by nitrous acid degradation and heparinase enzymes to analyze its structure in comparison with that of the fibroblast HS from which it was derived. The resultant fragments were separated on a Biogel P10 column (Fig. 4).


Fig. 4. Analysis of specific degradations of HS and PPD by gel filtration chromatography. 3H-Labeled HS (····) and PPD (------) were degraded by exhaustive treatment with low pH nitrous acid (A), heparinase III (B), and heparinase I (C) as described under "Experimental Procedures." The digests were analyzed by chromatography on a Bio-Gel P10 column. Distinct oligosaccharide peaks are labeled according to the number of monosaccharide units.
[View Larger Version of this Image (26K GIF file)]

Treatment with low pH nitrous acid, which cleaves at GlcNSO3 residues, yielded similar patterns of scission of PPD and HS, except for the striking difference in the disaccharide peak, which was 2-fold higher in PPD than in HS (Fig. 4A). This indicates a significant increase in contiguous N-sulfated disaccharides by comparison with the original HS. The overall level of N-sulfation was 61% in PPD compared with 39% in HS (Table I).

Table I. Susceptibility of PPD to cleavage with various specified agents

The 3H profiles in Fig. 4 were used to calculate the percentages of glycosidic bonds susceptible to cleavage by nitrous acid, heparinase I, or heparinase III in PPD and intact fibroblast HS, the latter of which is shown in parentheses.

Specific cleavage reagent Linkage specificitya Distribution of cleaved linkagesb
Total linkages cleaved
Contiguous Alternate Spaced

%
HNO2 GlcNSO3-HexA 35 (17) 16 (15) 10 (7) 61 (39)
Heparinase I GlcNSO3-IdoA(2-OSO3) 14 (5) 2 (1) 5 (7) 21 (13)
Heparinase III GlcNR-GlcA 36 (56) 3 (6) 13 (6) 53 (68)

a These disaccharide structures can also contain O-sulfate at appropriate C-2 and C-6 positions. Only O-sulfates absolutely essential to the reagent specificity are detailed. Abbreviations used are: HexA, alpha -L-iduronate or beta -D-glucuronate; R, H or SO3.
b Contiguous linkages give rise to disaccharide products. Alternate susceptible linkages possess single intervening resistant linkages and therefore give rise to tetrasaccharide products. Spaced susceptible linkages have two or more intervening resistant linkages, thereby giving hexasaccharide and larger oligosaccharide products.

Heparinase III scission provides data on the size range of the S-domains in HS, elucidating in part the arrangement of the contiguous N-sulfated disaccharides identified by nitrous acid hydrolysis. Heparinase III yielded distinctive patterns of scission of PPD and HS (Fig. 4B). There was a notable depletion of heparinase III-susceptible linkages in PPD (53% compared with 68% in HS), with significant enrichment of hexa- and octasaccharide S-domains (Fig. 4B, Table I).

There was also a notable increase in heparinase I-susceptible IdoA 2-O-sulfate containing disaccharides in PPD compared with the original HS (Fig. 4C, Table I). Heparinase I cleavage released 3-fold more disaccharides and twice the amount of tetrasaccharides from PPD than from the original HS. Since there were no midsized fragments released (Fig. 4C), the IdoA 2-O-sulfates must be toward the ends of PPD. As described earlier (Fig. 2C) on CL6B Sepharose, heparinase I-treated PPD eluted in a peak that overlapped with the position of PPD itself but with a peak maximum at 1 kDa smaller, confirming that only the end termini of PPD must have been cleaved. Since the use of partially desulfated heparins had indicated that IdoA 2-sulfate residues are important in the binding of polysaccharide to PF4, the affinity of heparinase 1-treated PPD for PF4 was investigated. This had no binding apparent above 0.3 M NaCl in the filter binding assay (data not shown) and hence much lower affinity for PF4 than PPD, which bound up to 0.6 M (Fig. 3A).

The prevalence in PPD of particular sized fragments in heparinase III and I digestions and nitrous acid hydrolysates can be rationalized in the form of a major structural motif, with some permissible variations, that represents this enzyme-protected binding region for PF4 in HS. Such a structure is depicted in Fig. 5A in the form of a model where the important IdoA 2-sulfate disaccharides are within short S-domains (three or four disaccharides) at opposite ends of the approximately 21-disaccharide PPD. The S-domains are separated by an extended region of relatively low sulfation that contains the cleavage sites for heparinase III (Fig. 5A). A model of PF4-PPD complex is also shown (Fig. 5B).


Fig. 5. Diagrammatic models of PPD structure and of the PPD·PF4 complex. Panel A depicts an empirically determined structure for PPD based on frequencies of nitrous acid and heparinase enzyme cleavage sites and the composition of resistant fragments (see Figs. 2A and 4 and Table I). Small open circles, GlcA-GlcNAc; striped loops, GlcA-GlcNSO3; spotted loops, IdoA-GlcNSO3; filled loops, IdoA(2S)-GlcNSO3, where 2S represents 2-O-sulfate. The upper arrows and lower arrows indicate nitrous acid and heparinase III cleavage sites, respectively. Panel B depicts a speculative model of the interaction of HS/PPD with the PF4 tetramer. The large ovoid slabs represent the beta -sheet structure of the PF4 monomers, with the positions of the triple loop alpha -helices containing the lysine clusters represented by the round ended rectangles. This back-to-back model of the PF4 dimer pairs is based on the recent crystallographic study of Zhang et al. (36). The cationic charges of the alpha -helical lysines (residues 61, 62, 65, and 66) and two of the arginines (residues 20 and 22) also known to be important in heparin binding (13) are depicted as +. It is proposed that binding is mediated primarily by the S-domains at the ends of PPD interacting with the alpha -helices on opposite sides of the PF4 tetramer and that the binding complex is stabilized by interactions of the flexible central portion of PPD binding to the positively charged protein surface. In this way an extended region of PF4-bound HS is protected from digestion with heparinase enzymes. Only <FR><NU>2</NU><DE>3</DE></FR> of PPD in B is visible and is depicted bound to the ring of positive charges on PF4 perpendicular to the alpha -helices. The remaining third, which has looped out of sight, will bind down the opposite face of PF4 across the pair of alpha -helices in the same fashion as indicated for the facing PF4 dimer.
[View Larger Version of this Image (26K GIF file)]


DISCUSSION

We have demonstrated by Scatchard analysis that a 1:1 ratio of HS to PF4 tetramer binds with a Kd of 16 nM, compared with 30 nM previously reported for the more highly sulfated heparin (12). Our results from competitive inhibition studies demonstrated the importance of S-domains in binding of HS to PF4, since heparinase I digestion caused a 3-fold increase in the IC50. However S-domains alone, isolated by heparinase III digestion, were unable to reproduce the binding properties of the parent molecule. These findings are in contrast to those for bFGF and for the extracellular matrix molecule, fibronectin, where the optimum HS binding sites appear to be contained within one extended sulfated domain (28, 31). The use of partially desulfated heparins emphasized the importance of 2-O-sulfate groups present on the IdoAs for binding to PF4, with possibly some requirement for 6-O-sulfation of the glucosamines, but N-sulfate groups were not necessary. Since IdoA 2-sulfate residues are also essential for bFGF binding to HS (28), PF4 may inhibit bFGF activity by competing for an overlapping site. However it cannot be ruled out that removal of these groups could have an effect on the secondary structure of HS that could be detrimental to its binding to PF4.

The foregoing results on the effects of enzyme scission and competing polysaccharide on the binding of HS to PF4 are not consistent with an interaction that is dependent solely on charge density. Reduction of net charge on PF4 mutants also affected heparin binding less than would be expected if charge alone were responsible for the interaction (13), and it was suggested that aggregation of the monomers contributed to the strength of interaction (32). This suggestion has been taken into account in our model of the PF4·PPD complex (Fig. 5B).

The most striking difference with most other previously characterized binding sites on HS is the unusually large molecular mass (9.3 kDa, equivalent to 21 disaccharides) of the PF4-binding fragment (PPD) isolated from murine fibroblast HS. This correlates with earlier reports showing a requirement of at least 10-kDa heparin fragments for optimum binding to this protein (15, 16). The disaccharide composition and the depolymerization profiles after specific enzyme and chemical scission (Fig. 4, Table I) were used to determine key structural features of PPD shown in the model in Fig. 5A.

The heparinase III depolymerization profile (Fig. 4B) indicates that murine 3T3 fibroblast HS in common with human fibroblast HS (33) largely consists of blocks of 3-7 N-sulfated disaccharides (i.e. the S-domains) spaced apart by extended N-acetylated sequences. The 21-disaccharide PPD contains on average 13 N-sulfated disaccharides, 61% of which are contiguous, i.e. present in S-domains (Table I). Therefore, four of the predominant hexa- and octasaccharide S-domains (Fig. 4B) may be accommodated in PPD (Fig. 5A). Heparinase I cleavage of the 9.3-kDa PPD only reduced its size by approximately 1 kDa (Fig. 2C) and released di- and tetrasaccharides (Fig. 4C, Table I), indicating that these susceptible IdoA 2-sulfate-containing S-domains (34) may be toward the ends of PPD (Fig. 5A). The four S-domains have been depicted as pairs at each end of the PPD model (Fig. 5A), although in a minority of cases each or either pair are merged into a single larger S-domain (10-14 saccharides), which were present in some PPD fragments (Fig. 4B). The proportion of GlcA-containing disaccharides in PPD (Fig. 4B, Table I) represents seven contiguous disaccharides, which are shown in the center of the model (Fig. 5A). Two N-sulfated disaccharides must be positioned within this central region (Fig. 5A) to account for the range of sizes of nitrous acid-resistant N-acetylated fragments seen in Fig. 4A. The presence of both sulfated and nonsulfated domains in PPD and the high level of 2-O-sulfation supports the sequence requirements deduced from the competitive inhibition studies.

A protection study similar to that described here was used to identify the binding site in heparan sulfate for the interferon-gamma dimer (35). A protected fragment of 10 kDa was isolated that shares some structural features with PPD. However, the interferon-gamma binding domain (named IPD) apparently contained only one S-domain at each end of the fragment and a greater prevalence of central linkages cleaved by heparinase III. In common with the PPD structure described in the present study, the peripheral S-domains in IPD were essential for the binding activity of interferon-gamma .

The large size of PPD favors the hypothesis that it wraps around the PF4 tetramer, neutralizing the ring of positive charges (Fig. 5B), as has been postulated for heparin (13, 17, 36, 37). 34 saccharides running perpendicular to the alpha -helices around PF4 have been proposed from x-ray crystallographic models to be the minimum number to form salt links with all four lysines of each monomer (17). The 42 saccharides of PPD may be accommodated into a perpendicular model with the extra central N-acetylated disaccharides looping out slightly from the tetramer. The paired nature of the S-domains, which contain the important IdoA 2-sulfate residues, at the ends of PPD, favors this model, since they would be in a position to interact with the lysine clusters in the pairs of antiparallel alpha -helices at opposite sides of the PF4 tetramer (Fig. 5B). Other important cationic residues, such as arginines 20, 22, and 46 (13), which encircle PF4, would interact with the GlcA and occasional N-sulfated groups in the central region of PPD (Fig. 5B).

A number of the basic residues in the ring of charges on PF4 are conserved within the family of intercrine chemokines (17), which includes interleukin-8, beta -thromboglobulin, neutrophil-activating protein-1, interferon-gamma -induced protein-10, and gro-alpha , -beta , and -gamma , emphasizing their likely physiological importance for chemokine function. Similarity in the x-ray crystallographic structure of interleukin-8 to PF4 infers that HS may also encompass interleukin-8, although it may recognize a different structural domain from PF4 (38). The distinctive nature of PF4 binding to HS and the specificity of the interaction strongly suggest important biological and biochemical properties of the HS·PF4 complex. At sites of vascular injury where platelet activation occurs, the concentration of PF4 can rise to 170 µM (1) (compared with 0.45 nM in unstimulated plasma), strongly favoring its binding with vascular HS. This should effectively block the binding of anticoagulant proteases such as antithrombin III to sequences within the S-domains of HS and thus favor blood coagulation. Furthermore, the accumulation of PF4 in wounds should promote the chemotactic action of PF4 on the subendothelial fibroblasts and weakly responsive neutrophils (1). The specificity of the interaction of PF4 with HS may enable it to bind preferentially to the HS at sites of active angiogenesis (7), which might account for its ability to inhibit angiogenesis and suppress tumor growth (8, 9). The model of an extended region of HS tethered by peripheral S-domains encircling subunits of PF4 could be a common mechanism of interaction with multimeric cytokines (35) and strengthens the view that the spacing of the S-domains within HS may be as critical for protein binding as the sulfation patterns (39).


FOOTNOTES

*   This work was supported by the Cancer Research Campaign.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed. Tel.: 44 161 446 3035; Fax: 44 161 446 3109.
1   The abbreviations used are: PF4, platelet factor 4; HS, heparan sulfate(s); bFGF, basic fibroblast growth factor; IdoA, alpha -L-iduronate; GlcA, beta -D-glucuronate; PPD, PF4-protected domain; IPD, interferon-gamma -protected domain; GlcNSO3, alpha -D-N-sulfoglucosamine.

ACKNOWLEDGEMENTS

We thank Chand Rana and Naomi Chadderton for technical assistance and Dr. Duncan Pepper (National Blood Transfusion Service, Edinburgh) for the kind provision of PF4. Help from Dr. Theodore Maione (36) in creating the model of PF4 structure was greatly appreciated.


REFERENCES

  1. Zucker, M. B., and Katz, J. R. (1991) Proc. Soc. Exp. Biol. Med. 198, 693-702 [Medline] [Order article via Infotrieve]
  2. Lane, D. A., Denton, J., Flynn, A. M., Thunberg, L., and Lindahl, U. (1984) Biochem. J. 218, 725-732 [Medline] [Order article via Infotrieve]
  3. Sato, Y., Abe, M., and Takaki, R. (1990) Biochem. Biophys. Res. Commun. 172, 595-600 [Medline] [Order article via Infotrieve]
  4. Gengrinovitch, S., Greenberg, S. M., Cohen, T., Gitay-Goren, H., Rockwell, P., Maione, T. E., Levi, B.-Z., and Neufeld, G. (1995) J. Biol. Chem. 270, 15059-15065 [Abstract/Free Full Text]
  5. Whitson, R. H., Wong, W. L., and Itakura, K. (1991) J. Cell Biochem. 47, 31-42 [Medline] [Order article via Infotrieve]
  6. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F., and Sharpe, R. J. (1990) Science 247, 77-79 [Medline] [Order article via Infotrieve]
  7. Hansell, P., Maione, T. E., and Borgstrom, P. (1995) Am. J. Physiol. 269, H829-H836 [Abstract/Free Full Text]
  8. Kolber, D. L., Knisely, T. L., and Maione, T. E. (1995) J. Natl. Cancer Inst. 87, 304-308 [Abstract]
  9. Sharpe, R. J., Byers, H. R., Scott, C. F., Bauer, S. I., and Maione, T. E. (1990) J. Natl. Cancer Inst. 82, 848-853 [Abstract]
  10. Sato, Y., Waki, M., Ohno, M., Kuwano, M., and Sakata, T. (1993) Jpn. J. Cancer Res. 84, 485-488 [Medline] [Order article via Infotrieve]
  11. Handin, R. I., and Cohen, H. J. (1976) J. Biol. Chem. 251, 4273-4282 [Abstract]
  12. Loscalzo, J., Melnick, B., and Handin, R. I. (1985) Arch. Biochem. Biophys. 240, 446-455 [Medline] [Order article via Infotrieve]
  13. Mayo, K. H., Ilyina, E., Roongta, V., Dundas, M., Joseph, J., Lai, C. K., Maione, T., and Daly, T. J. (1995) Biochem. J. 312, 357-365 [Medline] [Order article via Infotrieve]
  14. Mayo, K. H., and Chen, M.-J. (1989) Biochemistry 28, 9469-9478 [Medline] [Order article via Infotrieve]
  15. Ibel, K., Poland, G. A., Baldwin, J. P., Pepper, D. S., Luscombe, M., and Holbrook, J. J. (1986) Biochim. Biophys. Acta 870, 58-63 [Medline] [Order article via Infotrieve]
  16. Marshall, S. E., Luscombe, M., Pepper, D. S., and Holbrook, J. J. (1984) Biochim. Biophys. Acta 797, 34-39 [Medline] [Order article via Infotrieve]
  17. Stuckey, J. A., St-Charles, R., and Edwards, B. F. P. (1992) Proteins Struct. Funct. Genet. 14, 277-287 [Medline] [Order article via Infotrieve]
  18. Kolset, S. O., and Gallagher, J. T. (1990) Biochim. Biophys. Acta 1032, 191-212 [CrossRef][Medline] [Order article via Infotrieve]
  19. Kjellen, L., and Lindahl, U. (1991) Annu. Rev. Biochem. 60, 443-475 [CrossRef][Medline] [Order article via Infotrieve]
  20. Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M. T., Spring, J., Gallo, R. L., and Lose, E. J. (1992) Annu. Rev. Cell Biol. 8, 365-393 [CrossRef]
  21. Busch, C., Dawes, J., Pepper, D. S., and Wasteson, Å. (1980) Thrombosis Res. 19, 129-137 [Medline] [Order article via Infotrieve]
  22. Bock, P. E., Luscombe, M., Marshall, S. E., Pepper, D. S., and Holbrook, J. J. (1980) Biochem. J. 191, 769-776 [Medline] [Order article via Infotrieve]
  23. Taylor, R. L., Shively, J. E., Conrad, H., and Cifonelli, J. A. (1973) Biochemistry 12, 3633-3637 [Medline] [Order article via Infotrieve]
  24. Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T., and Gallagher, J. T. (1994) J. Biol. Chem. 269, 11216-11223 [Abstract/Free Full Text]
  25. Maccarana, M., and Lindahl, U. (1993) Glycobiology 3, 271-277 [Abstract]
  26. Shively, J. E., and Conrad, H. E. (1976) Biochemistry 15, 3943-3950 [Medline] [Order article via Infotrieve]
  27. Klotz, I. M. (1982) Science 217, 1247-1249 [Medline] [Order article via Infotrieve]
  28. Turnbull, J. E., Fernig, D. E., Kie, Y., Wilkinson, M. C., and Gallagher, J. T. (1992) J. Biol. Chem. 267, 10337-10341 [Abstract/Free Full Text]
  29. Lindhardt, R. J., Turnbull, J. E., Wang, H. M., Loganathan, D., and Gallagher, J. T. (1990) Biochemistry 29, 2611-2617 [Medline] [Order article via Infotrieve]
  30. Wasteson, Å. (1971) J. Chromatogr. 59, 87-97 [CrossRef][Medline] [Order article via Infotrieve]
  31. Walker, A., and Gallagher, J. T. (1996) Biochem. J. 317, 871-877 [Medline] [Order article via Infotrieve]
  32. Mayo, K. H. (1991) Biochemistry 30, 925-934 [Medline] [Order article via Infotrieve]
  33. Turnbull, J. E., and Gallagher, J. T. (1991) Biochem. J. 273, 553-559 [Medline] [Order article via Infotrieve]
  34. Turnbull, J. E., and Gallagher, J. T. (1990) Biochem. J. 265, 715-724 [Medline] [Order article via Infotrieve]
  35. Lortat-Jacob, H., Turnbull, J. E., and Grimaud, J.-A. (1995) Biochem. J. 310, 497-505 [Medline] [Order article via Infotrieve]
  36. Zhang, X., Chen, L., Bancroft, D. P., Lai, C. K., and Maione, T. E. (1994) Biochemistry 33, 8361-8366 [Medline] [Order article via Infotrieve]
  37. St. Charles, R., Walz, D. A., and Edwards, B. F. P. (1989) J. Biol. Chem. 264, 2092-2099 [Abstract/Free Full Text]
  38. Webb, L. M. C., Ehrengruber, M. U., Clarke-Lewis, I., Baggiolini, M., and Rot, A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7158-7162 [Abstract]
  39. Stringer, S. E., and Gallagher, J. T. (1997) Int. J. Biochem. & Cell Biol., in press

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.